Dapoxetine

Dapoxetine (LY 210448) is a short-acting selective serotonin reuptake inhibitor (SSRI) and the first oral pharmacotherapy specifically developed and approved for the on-demand treatment of premature ejaculation (PE) in adult men aged 18 to 64 years. Originally synthesized at Eli Lilly and Company as an antidepressant candidate in the late 1980s, the compound was shelved after failing to demonstrate sufficient efficacy in depression, subsequently licensed to Pharmaceutical Product Development (PPD) in 2003, and then advanced through Phase 3 clinical development by ALZA Corporation (a Johnson and Johnson subsidiary) for the PE indication. Dapoxetine received its first regulatory approvals in Finland and Sweden in 2009 under the trade name Priligy and has since been registered in over 60 countries across Europe, Asia, Latin America, and Oceania. The compound has not been approved by the United States Food and Drug Administration, which issued a not-approvable letter in 2005 citing the need for additional efficacy and safety data.

The pharmacological mechanism of dapoxetine is inhibition of the serotonin transporter (SERT) at both peripheral and central sites, increasing serotonin availability at postsynaptic receptors in the ejaculatory pathway. Preclinical electrophysiology studies in anaesthetized rats demonstrated that dapoxetine inhibits the ejaculatory expulsion reflex at a supraspinal level, specifically modulating activity of lateral paragigantocellular nucleus (LPGi) neurons that project to spinal ejaculatory motor centers. The compound exhibits high selectivity for the serotonin transporter over the norepinephrine and dopamine transporters, with Ki values of approximately 1.0 nM for SERT, 66 nM for the norepinephrine transporter, and greater than 1000 nM for the dopamine transporter.

The critical pharmacokinetic distinction of dapoxetine from conventional SSRIs (paroxetine, fluoxetine, sertraline, citalopram) is its rapid absorption and elimination profile. After oral administration, dapoxetine reaches maximum plasma concentration (Cmax) within approximately 1.0 to 1.3 hours, with an initial distribution half-life of 1.3 to 1.4 hours and a terminal elimination half-life of 18.7 to 21.9 hours. Oral bioavailability is approximately 42 percent, with substantial interindividual variability (range 15 to 76 percent) attributable to first-pass hepatic metabolism. Metabolism proceeds through CYP3A4, CYP2D6, and flavin-containing monooxygenase 1 (FMO1) pathways, producing dapoxetine N-oxide (inactive), N-desmethyldapoxetine (active), and N,N-didesmethyldapoxetine (active) as the principal circulating metabolites. Plasma protein binding exceeds 99 percent.

Five pivotal Phase 3 randomized, double-blind, placebo-controlled trials enrolling 6,081 men across more than 25 countries established the clinical efficacy of dapoxetine at 30 mg and 60 mg on-demand doses. Integrated analysis demonstrated that mean intravaginal ejaculatory latency time (IELT) increased from a baseline of 0.9 minutes to 3.2 minutes with dapoxetine 30 mg and 3.5 minutes with dapoxetine 60 mg, compared to 1.9 minutes with placebo. Statistically significant improvements were observed across all patient-reported outcome domains including ejaculatory control, satisfaction with sexual intercourse, ejaculation-related personal distress, and interpersonal difficulty. The safety profile is consistent with the SSRI pharmacological class; the most common adverse events are nausea (8.7 to 20.1 percent), dizziness (5.8 to 10.9 percent), headache (5.6 to 8.8 percent), diarrhea (3.9 to 6.8 percent), and somnolence. A specific safety concern is vasovagal-mediated syncope, observed at rates of 0.06 percent with 30 mg and 0.23 percent with 60 mg compared to 0.05 percent with placebo. Dapoxetine is contraindicated with potent CYP3A4 inhibitors, monoamine oxidase inhibitors, other serotonergic agents, and in patients with significant cardiovascular disease or a history of syncope.

This monograph reviews the chemistry, synthesis, and stereochemistry of dapoxetine; the serotonin transporter pharmacology and supraspinal ejaculatory reflex modulation mechanism in molecular and electrophysiological detail; the comprehensive human pharmacokinetic record including CYP2D6 and CYP3A4 metabolic polymorphism; the clinical evidence base across premature ejaculation and combination therapy with phosphodiesterase type 5 inhibitors; the reconstitution, sourcing, and quality verification considerations for laboratory work; stack-interaction implications; adverse-event signal including syncope and serotonin syndrome risk; and a comparative assessment of five alternative premature ejaculation pharmacotherapies against dapoxetine on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).